ABBV-744 clinical trial phase 2 data Things To Know Before You Buy
The present work examined the potential of utilizing ARV-825 and ABBV-744 to increase the effectiveness of tamoxifen or fulvestrant moreover palbociclib. ARV-825 was effective in both p53 wild-form (WT) breast tumor cells and in cells lacking practical p53 both alone or in combination with tamoxifen, while the effectiveness of ABBV-744 was limited